深陷医药行贿丑闻，信邦制药（002390.SZ）被检察机关移送起诉。 12月10日晚，信邦制药发布公告，公司涉嫌单位行贿一案，检察机关已经收到监察委员会移送起诉的材料。 点击蓝字关注我们 长江商报记者 沈右荣 2025年2月，贵阳开阳县人民法院立案受理贵州科开医药有限公司（以下简称"科开医药"）涉嫌单位行贿罪、安怀略涉嫌行贿罪一案。科开医药系信邦制 药控股子公司，安怀略系信邦制药前董事长，现任董事长安吉之父。 此案的刑事判决，将对信邦制药产生多大影响，暂且无从知晓。二级市场上，12月11日、12日，信邦制药股价连续跌停。 信邦制药是一家覆盖医疗服务、医药流通和医药制造的医疗健康全产业链集团，2010年登陆A股市场。 近年来，信邦制药经营业绩萎靡。2024年及2025年前三季度，公司业绩持续双降。 信邦制药研发投入不多。2025年前九个月，公司的研发投入为429.26万元。与之对应的是，公司销售费用1.96亿元，大幅高于研发投入。 公司及子公司均涉单位行贿 信邦制药及其控股子公司均涉嫌单位行贿。 根据公告，近日，信邦制药收到了检察机关《审查起诉阶段委托辩护人/申请法律援助告知书》《犯罪嫌疑人诉讼权利义务告知书》 ...

12月10日晚，信邦制药发布公告，公司涉嫌单位行贿一案，检察机关已经收到监察委员会移送起诉的材 料。 长江商报消息 ●长江商报记者 沈右荣 深陷医药行贿丑闻，信邦制药（002390.SZ）被检察机关移送起诉。 2025年2月，贵阳开阳县人民法院立案受理贵州科开医药有限公司（以下简称"科开医药"）涉嫌单位行 贿罪、安怀略涉嫌行贿罪一案。科开医药系信邦制药控股子公司，安怀略系信邦制药前董事长，现任董 事长安吉之父。 此案的刑事判决，将对信邦制药产生多大影响，暂且无从知晓。二级市场上，12月11日、12日，信邦制 药股价连续跌停。 信邦制药是一家覆盖医疗服务、医药流通和医药制造的医疗健康全产业链集团，2010年登陆A股市场。 近年来，信邦制药经营业绩萎靡。2024年及2025年前三季度，公司业绩持续双降。 信邦制药研发投入不多。2025年前九个月，公司的研发投入为429.26万元。与之对应的是，公司销售费 用1.96亿元，大幅高于研发投入。 公司及子公司均涉单位行贿 信邦制药及其控股子公司均涉嫌单位行贿。 根据公告，近日，信邦制药收到了检察机关《审查起诉阶段委托辩护人/申请法律援助告知书》《犯罪 嫌疑人诉讼权利义务 ...

【导读】涉嫌单位行贿，信邦制药被检察机关起诉 12月10日晚间，信邦制药（002390）发布公告称，公司涉嫌单位行贿，检察机关已收到监察委员会移送起诉的材料。 12月10日，信邦制药股价午盘异动，股价直线拉升涨停。截至收盘，该股报4.15元/股，总市值为80.67亿元。 信邦制药被检察机关起诉 12月10日晚间，信邦制药发布公告称，公司近日收到《审查起诉阶段委托辩护人/申请法律援助告知书》和《犯罪嫌疑人诉讼权利义务告知书》，对公司 涉嫌单位行贿一案，检察机关已收到监察委员会移送起诉的材料。 信邦制药表示，该事项可能对公司品牌声誉、业务拓展及未来发展产生不利影响。目前案件处于审查起诉阶段，最终结果以司法机关出具的法律文书为 准。 截至目前，公司控制权未发生变化，公司董事会、管理层履职正常，公司拥有完善的组织架构及规范的业务流程，公司及子公司日常经营正常。公司将依 法配合相关机关的工作，并委托辩护律师负责本案诉讼事宜，公司将持续关注本案后续的进展情况，及时履行信息披露义务。 子公司曾被立案 值得注意的是，信邦制药近年来负面消息频出。今年2月26日，贵州省开阳县人民法院发布公告，立案受理贵州科开医药有限公司单位行贿 ...

【导读】涉嫌单位行贿，信邦制药被检察机关起诉 12月10日晚间，信邦制药发布公告称，公司涉嫌单位行贿，检察机关已收到监察委员会移送起诉的材料。 12月10日，信邦制药股价午盘异动，股价直线拉升涨停。截至收盘，该股报4.15元/股，总市值为80.67亿元。 信邦制药被检察机关起诉 12月10日晚间，信邦制药发布公告称，公司近日收到《审查起诉阶段委托辩护人/申请法律援助告知书》和《犯罪嫌疑人诉讼权利义务告知书》，对公司 涉嫌单位行贿一案，检察机关已收到监察委员会移送起诉的材料。 信邦制药表示，该事项可能对公司品牌声誉、业务拓展及未来发展产生不利影响。目前案件处于审查起诉阶段，最终结果以司法机关出具的法律文书为 准。 截至目前，公司控制权未发生变化，公司董事会、管理层履职正常，公司拥有完善的组织架构及规范的业务流程，公司及子公司日常经营正常。公司将依 法配合相关机关的工作，并委托辩护律师负责本案诉讼事宜，公司将持续关注本案后续的进展情况，及时履行信息披露义务。 子公司曾被立案 值得注意的是，信邦制药近年来负面消息频出。今年2月26日，贵州省开阳县人民法院发布公告，立案受理贵州科开医药有限公司单位行贿罪、安怀略行 贿 ...

Core Viewpoint - Xinfang Pharmaceutical is facing legal challenges due to allegations of unit bribery, which may adversely affect its brand reputation and future business development [6][8]. Group 1: Legal Issues - On December 10, Xinfang Pharmaceutical announced that it has been prosecuted by the procuratorial authority for suspected unit bribery, following materials sent by the supervisory committee [6][8]. - The company has received legal documents regarding the prosecution and is currently in the review and prosecution stage [6][8]. - Xinfang Pharmaceutical has stated that it will cooperate with relevant authorities and has appointed defense lawyers for the case [8]. Group 2: Stock Performance - On December 10, the stock price of Xinfang Pharmaceutical experienced a significant increase, reaching a limit up of 10.08%, closing at 4.15 yuan per share, with a total market value of 80.67 billion yuan [3][15]. Group 3: Financial Performance - For the first three quarters of the year, Xinfang Pharmaceutical reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [14]. - The company's financial performance has been unstable, with a projected decline of over 60% in net profit attributable to shareholders for 2024 [14].

Core Viewpoint - Haosai is under investigation for suspected information disclosure violations, raising questions about potential bribery related to its performance and the competitive nature of its industry [1][2] Group 1: Company Background - Haosai's main business includes smart lighting, smart tourism, and smart cities, with lighting design and engineering as its core revenue source [4] - The industry is highly competitive, with demand influenced by economic cycles, macroeconomic policies, and local government finances [4] - The company's clients primarily consist of state-owned enterprises and government departments, utilizing bidding and negotiation for business acquisition [4] Group 2: Financial Performance - Since its listing in 2019, Haosai has faced continuous losses, with revenues declining from 7.88 billion in 2020 to 4.59 billion in 2024 [5] - In the first three quarters of 2025, the company reported revenues of 2.65 billion, a year-on-year decrease of 29.79%, and a net loss of 2631.38 million, a decline of 523.96% [6] Group 3: Internal Control and Compliance Issues - The company has faced scrutiny for its internal controls and compliance, receiving a regulatory warning for failing to disclose information timely [8] - The investigation into bribery and the subsequent legal actions against its former chairman highlight significant governance and operational deficiencies [2][8]

Core Viewpoint - Haosai (002963) has been sentenced for unit bribery, resulting in a fine of RMB 7 million and a total of approximately RMB 28.52 million in penalties and confiscated illegal gains, which represents 15.90% of the company's latest audited net profit [1][2] Group 1: Legal Proceedings - The Wuhan New District People's Court has ruled that Haosai committed unit bribery, leading to a fine of RMB 7 million, which has been paid [1] - The defendant, Dai Baolin, received a three-year prison sentence with a four-year probation and a fine of RMB 3 million, which has also been paid [1] - The court ordered the confiscation of RMB 21.52 million in illegal gains, which will be turned over to the national treasury [1] Group 2: Company Response and Governance - Haosai stated that the judgment does not trigger mandatory delisting rules under the Shenzhen Stock Exchange regulations and has apologized to investors, promising to enhance internal controls and governance [2] - The company has faced scrutiny for not timely disclosing the arrest of Dai Baolin and the investigation into the company, which led to regulatory warnings [4] Group 3: Financial Performance - Haosai's financial performance has deteriorated, with a reported revenue of RMB 265 million for the first three quarters of 2025, a year-on-year decline of 29.79% [5] - The company recorded a net loss of RMB 26.31 million, marking a shift from profit to loss compared to the previous year [5] - Contributing factors to the financial decline include reduced demand in the lighting engineering sector, increased competition, and extended customer payment cycles [5] Group 4: Business Strategy - In May 2025, Haosai expanded its business scope to include electric vehicle charging infrastructure operations, aiming to find new growth points through its new energy segment [6] - However, the financial penalties and confiscated funds from the bribery case may further strain the company's cash flow [6]

Core Viewpoint - The company, Haosai Technology Group Co., Ltd., is facing regulatory scrutiny due to allegations of bribery involving its controlling shareholder, Dai Baolin, who has been arrested. This has led to a significant decline in the company's financial performance and a change in its controlling shareholders [2][5]. Financial Performance - For the first half of 2025, the company reported total revenue of 158.06 million yuan, a decrease of 46.60% compared to the same period last year [7][8]. - The net profit attributable to shareholders was -33.71 million yuan, representing a decline of 538.56% year-on-year [7][8]. - The net cash flow from operating activities was -27.42 million yuan, a significant drop from 619.85 thousand yuan in the previous year [8]. Shareholding Structure - On July 29, 2025, Dai Baolin signed a voting rights entrustment agreement, transferring all voting rights of his 35,128,385 shares (23.36% of total shares) to Dai Congqi [5][6]. - Following this agreement, the controlling shareholders changed to Dai Congqi and Liu Qingmei, with Dai Baolin and others acting in concert with them [5][6]. Business Overview - The company's main business includes landscape lighting and new energy charging, with lighting services covering design, construction, sales, procurement, and operation [6]. - The company primarily serves government departments, large state-owned enterprises, and other clients, utilizing bidding and negotiation methods to secure contracts [6].

Core Points - The company received a warning letter from the Beijing Securities Regulatory Bureau regarding administrative regulatory measures against the company and its key individuals [1] - The controlling shareholder and actual controller, Dai Baolin, was arrested by public security authorities on June 19, 2025, for suspected unit bribery [1] - The company is under investigation by supervisory authorities for suspected unit bribery and failed to timely disclose relevant information [1] - The situation highlights deficiencies in the company's operational compliance, corporate governance, and internal controls [1]

Core Viewpoint - Galaxy Electronics' subsidiary, Hefei Tongzhi Electromechanical Control Technology Co., Ltd., is facing criminal charges for alleged bribery, which adds to the company's existing financial troubles and regulatory issues [1][4]. Group 1: Company Issues - The subsidiary, Tongzhi Electromechanical, has been banned from participating in military equipment procurement for 36 months due to previous violations [1]. - Galaxy Electronics reported a net loss of approximately 685 million yuan for 2024, a decrease of 466.46% year-on-year, primarily due to the impact of contract price audits on its subsidiary [4]. - The company has received a qualified audit opinion from its auditor, indicating ongoing investigations into its financial practices [4]. Group 2: Financial Impact - As of the end of last year, Tongzhi Electromechanical has submitted contract price refunds totaling 367 million yuan, with 220 million yuan in bank structured deposits being restricted [4]. - Galaxy Electronics expects a net loss of between 26 million and 32 million yuan for the first half of 2025, attributing this to reduced new orders and delayed revenue recognition [5]. - The company has adjusted its 2024 revenue by approximately 518 million yuan due to the aforementioned issues, including tax adjustments and impairment provisions [5].